Mekinist (trametinib) — United Healthcare
Used in combination with Tafinlar (dabrafenib)
Initial criteria
- Used in combination with Tafinlar (dabrafenib) OR
- Recognized by NCCN Drugs and Biologics Compendium with Category of Evidence and Consensus of 1, 2A, or 2B for treatment of the cancer indication
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Mekinist therapy
Approval duration
12 months